Using an MVT versus MVP to Maximize Lab-to-Field Transition Efforts

A. Carpenter
AxNano,
United States

Keywords: water, water treatment

Summary:

Lab-to-field testing is not just a technical feat. This important commercialization milestone must simultaneously address key technical hypotheses and key business assumptions. This talk will present lessons learned from the commercialization of AxNano’s first product, RemRx™ CRP, a controlled release treatment for contaminated groundwater, and current efforts on nano-enabled PFAS treatments and detection. We will discuss using a Minimum Viable Test versus a Minimum Viable Product-centric approach to preparing for field-scale. We will also discuss the non-technical considerations for pilot demonstration, such as “How do I find a test site?”, “What partnerships are needed?”, and “How do I manage data sharing/access?”.